

GDM: Cause of obesity, diabetes & CVD epidemic?

Prof P Saravanan MBBS PhD FRCP

Professor & Hon Consultant Physician

University of Warwick & George Eliot Hospital

MLHD, ICTS-TIFR Bengaluru 24 Jul 2023

- **Human evolution**
- **Gestational Diabetes**
 - Maternal risk
 - Offspring risk
- **Importance of innovative methodologies**
 - Learnings from birth weight studies
 - Need for accurate personalized prediction

Rank according to % body fat?



Humans




© John Hyde




TEAW



Humans



Humans



When does the process start?



- Human evolution
- **Gestational Diabetes**
 - Maternal risk
 - Offspring risk
- Importance of innovative methodologies
 - Learnings from birth weight studies
 - Need for accurate personalized prediction

What is GDM?



“Glucose intolerance resulting in hyperglycaemia (of varying severity) which *begins or first diagnosed* in pregnancy”


“Hyperglycaemia in pregnancy”

Currently diagnosed by OGTT
around 28 weeks of pregnancy

Requires fasting and 2-hr sample


Why worry about GDM?

Doubling of GDM



Doubling of GDM in USA in 14 years


GDM rates in Sweden



64% higher incidence of GDM in 10 years


>90% of GDM happens in developing countries

Pre-prediabetes?




T2D, HTn & CVD post GDM in UK

THIN database:
>9000 GDM
>37000 Controls




Fuel-mediated Teratogenesis

Permanent change in habitus caused by abnormal concentrations of nutrients during period of intrauterine development



Offspring effects



At birth




In early adulthood

Variables	O-GDM (n = 168)	O-NoGDM (n = 141)	O-Type1 (n = 160)	O-BP (n = 128)	<i>p</i> ^a
Offspring					
Age (yr)	21.6 (1.8) ^b	21.1 (2.1) ^b	22.5 (2.2)	22.9 (2.2)	<0.001
BMI ≥25 kg/m ²	40% (67/168) ^b	30% (42/141)	41% (66/160) ^b	24% (31/128)	0.005
BMI >30 kg/m ²	13% (21/168)	11% (16/141)	10% (16/160)	5% (6/128)	0.1
Metabolic syndrome ^c	24% (40/168) ^b	15% (21/141) ^b	14% (23/160)	6% (7/128)	<0.001
Central obesity (M >94 cm; W >80 cm)	39% (66/168)	38% (54/141)	43% (68/160)	29% (37/128)	0.1
Triglycerides ≥1.7 mmol/liter	16% (26/167) ^b	14% (20/140) ^b	6% (10/159)	5% (6/128)	0.002
Reduced HDL (M <1.03; W <1.29 mmol/liter)	37% (62/167) ^b	31% (43/140) ^b	20% (32/159)	13% (17/128)	<0.001
Diastolic blood pressure ≥85 mm Hg	4% (6/167)	2% (3/141)	5% (8/160)	2% (2/128)	0.3
Systolic blood pressure ≥130 mm Hg	37% (62/167)	31% (44/141)	41% (66/160) ^b	24% (31/128)	0.02
Fasting plasma glucose ≥5.6 mmol/liter	41% (69/167) ^b	30% (42/138) ^b	25% (39/155) ^b	10% (13/128)	<0.001
Physical activity (≥30 min/d)	56% (94/168)	56% (79/141)	48% (77/160)	50% (64/128)	0.4
Smokers	46% (77/168)	42% (59/141)	36% (57/160)	35% (45/128)	0.2
Parents					
Paternal diabetes	8% (13/164)	8% (11/136)	5% (8/157)	9% (11/125)	0.6
Family occupational social class V or VI	27% (45/167) ^b	18% (25/140)	18% (29/160) ^b	8% (10/128)	<0.001

Pre-diabetes/T2D (adj. ORs):	7.76	4.46	4.02	ref
-------------------------------------	-------------	-------------	-------------	------------

CVD in offspring post GDM



No at risk

Unexposed

2 377 136 2 062 027 1 759 037 1 450 866 1 127 219 787 639 490 892 246 601 0

Exposed

54 864 36 959 22 961 13 816 7591 4369 2394 998 0

Why worry about GDM?

Panel: Long-term complications of gestational diabetes

Complications for the women

- Hypertension⁸
- Type 2 diabetes^{8,24,25}
- Vascular dysfunction⁴¹
- Non-alcoholic fatty liver disease^{42,43}
- Dyslipidaemia^{8,24,25}
- Chronic inflammation^{41,44}
- Chronic kidney disease^{45,46}
- Ischaemic heart disease^{8,9}

Complications for the offspring

- Childhood obesity^{10,25}
- Excess abdominal adiposity⁴⁷
- Metabolic syndrome^{48,49}
- Hyperinsulinaemia⁵⁰
- Disordered glucose regulation in adolescents²⁷
- Higher blood pressure^{51,52}
- Possible early onset of cardiovascular disease⁵³
- Possible attention-deficit hyperactivity disorder and autism spectrum disorders^{52,54,55}

- Human evolution
- Gestational Diabetes
 - Maternal risk
 - Offspring risk
- **Importance of innovative methodologies**
 - Learnings from birth weight studies
 - Need for accurate personalized prediction

Why we need innovative methodologies?

Treating GDM may be too late?

Treatment: ~50% risk reduction

**2 landmark studies: Crowther et al &
Landon et al**

Neonatal adiposity in GDM

Total adiposity measured by MRI Spectroscopy scan in the first 2 weeks and then at 8-12 weeks; Well controlled GDM; n= 86

Outcomes	Model 1			Model 2		
	Difference (%)	95% CI	P value	Difference (%)	95% CI	P value
Assessment 1						
Total AT	6.9	-1.4, 15.9	0.11	5.4	-3.6, 15.6	0.24
Internal abdominal AT/nonabdominal superficial subcutaneous AT ratio				1.2	-11.3, 15.6	0.86
IHCL*						
Assessment 2						
Total AT	16.0	6.0, 27.1	0.002	12.5	1.0, 25.0	0.03
Change in total AT	35.8	11.7, 65.2	0.003	32.4	5.2, 66.3	0.02
Internal abdominal AT/nonabdominal superficial subcutaneous AT ratio				-0.2	-15.1, 17.2	0.98
IHCL	5.7	-30.2, 59.6	0.79	3.5	-35.4, 65.6	0.89


Model 1, adjustment of AT for body size using indices (18) (not applicable for AT ratios) and IHCL for postnatal age; model 2, same as model 1 plus adjustment for infant sex and maternal prepregnancy BMI. *Non-normal distribution, and therefore the percentage difference, was not calculable.

Fetal adiposity precedes onset of GDM

Control




GDM



Glucose does not explain everything!

Birth weight & risk of GDM



U shaped relation
Both low and high BW association
Intergenerational risk transmission

Born to GDM



Ethnic differences



	All women (N=10 356)		White British women (N=4105)		South Asian women (N=5445)	
	Fasting glucose threshold (mmol/L)	2 h post-load glucose threshold (mmol/L)	Fasting glucose threshold (mmol/L)	2 h post-load glucose threshold (mmol/L)	Fasting glucose threshold (mmol/L)	2 h post-load glucose threshold (mmol/L)
Birthweight >90th percentile	5.3	NP	5.6	NP	5.1	NP
Sum skinfolds >90th percentile	5.2	7.5	5.2	NP	5.2	7.2
Average glucose concentration for both birthweight and sum of skinfolds >90th percentile	5.3	7.5	5.4	NP	5.2	7.2

NP=not possible to work out a threshold because within our study none of the women reached a threshold that gave an odds ratio of 1.75 or greater (the International Association of Diabetes and Pregnancy Study Groups consensus minimal odds ratio deemed to be of clinical importance).

Thresholds of glucose concentrations and OR ~1.75 for birthweight >90th and sum of skinfolds >90th percentiles


GDM were excluded; GDM diagnosed if FPG ≥6.1 and 2-hr ≥7.8 mmol/l (110 and 140mg/dl)

Risk factors for GDM

- Age (lowest <20yrs)
- BMI more than 30
- Previous macrosomic baby (4.5kg)
- Previous GDM
- PCOS
- First degree relative with diabetes
- Polyhydramnios & fetal abdo circumference >97 centile
- Certain ethnic groups:
 - South Asian (India, Pakistan or Bangladesh)
 - Black & Afro-Caribbean
 - Middle Eastern (Saudi Arabia, UAE, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, Lebanon or Egypt)

- **Known risk factors only picks up ~60% of all GDM**
 - Need for identification of other markers
 - n=4500; 10 centres
- **Damage to the offspring may have already happened**
 - Accurate early pregnancy prediction can prevent GDM

Study flow





Baseline characteristics: Early pregnancy

Maternal Characteristics at Booking	All (n=4746) Mean ± SD Median (IQR) [§] n (%) [^]	Whites (n=3488) Mean ± SD Median (IQR) [§] n (%) [^]	South Asians (n=769) Mean ± SD Median (IQR) [§] n (%) [^]	Others (n=489) Mean ± SD Median (IQR) [§] n (%) [^]	p-value
Age (years)	30.51 ± 5.29	30.1 ± 5.35	31.57 ± 4.72	31.4 ± 5.4	<0.0001
Multi parity (≥2) [^]	919 (19.4)	698 (20.0)	119 (15.5)	102 (20.9)	0.01
Gestational age (weeks)	12.45 ± 1.44	12.39 ± 1.47	12.51 ± 1.39	12.8 ± 1.21	<0.0001
Height (cm)	164.28 ± 6.83	165.32 ± 6.64	160.69 ± 6.24	162.57 ± 6.84	<0.0001
Weight (kg)	83.33 ± 20.49	88.3 ± 19.6	66.44 ± 13.93	74.44 ± 18.04	<0.0001
BMI (kg/m²)	30.8 ± 7.06	32.3 ± 6.92	25.7 ± 4.96	28.1 ± 6.27	<0.0001
Waist Circumference (cm)[^]	98.54 ± 16.41	101.9 ± 15.95	87.73 ± 12.78	91.45 ± 15.16	<0.0001
Biochemical characteristics	n=4630	n=3396	n=759	n=475	
B12 (pmol/l)[§]	238.2 (183.3, 311.2)	230.3 (181.1, 298.0)	233.3 (177.9, 319.9)	316.5 (237.3, 429.3)	<0.0001
Folate (nmol/l)[§]	35.9 (24.8, 52.2)	33.8 (23.2, 51.3)	43.0 (30.4, 54.0)	38.3 (27.0, 51.6)	<0.0001
tHcy (μmol/l) ^{§b}	11.3 (8.6, 14.7)	11.4 (8.7, 14.8)	11.1 (8.7, 14.7)	10.9 (8.3, 13.8)	0.12
B12 insufficiency at <150pmol/l[^]	490 (10.6)	365 (10.7)	101 (13.3)	23 (4.8)	<0.0001
B12 insufficiency at <220pmol/l[^]	1985 (42.8)	1536 (45.2)	348 (45.8)	98 (20.6)	<0.0001
Folate deficiency (<10nmol/l)[^]	69 (1.5)	61 (1.8)	1 (0.1)	7 (1.5)	0.003
Folate excess (>45nmol/l)[^]	1640 (35.4)	1139 (33.5)	342 (45.1)	159 (33.5)	<0.0001
Using Folate supplements [^]	3424 (78.2)	2569 (79.5)	526 (76.0)	329 (72.3)	<0.0001
Using Multivitamin supplements [^]	2494 (58.1)	1840 (58.2)	425 (62.7)	229 (50.9)	<0.0001



Relationship between B12-folate with glucose

Fasting glucose




Spline regression analysis

2-hour post glucose





B12-folate imbalance and GDM

'Low B12 and high folate' with NICE-GDM




'Low B12 and high folate' with IADPSG-GDM






IADPSG: International Association of Diabetes and Pregnancy Study Group
GDM: Gestational Diabetes Mellitus

GLP1 levels in GDM



Sukumar N et al, Diabetes 2018

Hypertriglyceridemic waist and GDM




- Measured at 11-14 wks
- 75g OGTT at 24-28 wks
- Waist >85cms, + TG>1.7mM = OR 6.1
- Disturbed metabolism from early pregnancy

Brisson D et.al, CMAJ 2010.

Adiponectin

Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis

Stamatina Iliodromiti¹ · Jennifer Sassarini¹ · Thomas W. Kelsey² · Robert S. Lindsay³ · Naveed Sattar³ · Scott M. Nelson¹



Diastolic BP


Table 2 Multivariable regression analysis result for formulating the composite risk score

	B	Adjusted OR (95% CI)	P Value



Fang Q et al, (submitted)

Composite risk score



Fang Q et al, (submitted)

- **Adverse disease programming is complex**
- **Identification of novel risk predictors is evolving rapidly**
- **Ethnic variations**
- **Factors that affect mothers may not affect offspring and vice versa**

- **Composite risk prediction**
- **Personalization**
- **Accounting for inter- and intra individual variations**
- **Availability of better datasets**

- Human evolution – **Still a long way to go...**
- Gestational Diabetes – **Contributes to CVD epidemic; potentially other neurodevelopmental issues**
- Importance of innovative methodologies – **Complex issues & simple analyses cannot solve**


Conclusion - 1



Conclusion - 2



My funders



Thank you

